Levi & Korsinsky Alerts Altimmune, Inc. Investors of Class Action Lawsuit and Deadline

Investors who have invested in Altimmune, Inc. (ALT) have been notified by Levi & Korsinsky, LLP about a class action lawsuit against the company. This lawsuit has been filed on behalf of shareholders who purchased Altimmune, Inc. securities between May 18, 2021, and August 30, 2021.

The class action lawsuit alleges that Altimmune, Inc. made misleading statements and failed to disclose important information regarding the company’s HepTcell Phase 1/2 clinical trial. The lawsuit claims that Altimmune, Inc. misrepresented the primary endpoint of the clinical trial and failed to disclose setbacks that the trial faced.

The HepTcell Phase 1/2 clinical trial was evaluating the safety and effectiveness of the company’s HepTcell therapy for the treatment of chronic hepatitis B virus (HBV) infection. The lawsuit alleges that Altimmune, Inc. falsely stated that the primary endpoint of the trial was the percentage of patients with at least one adverse event, when in fact, the primary endpoint was the percentage of patients achieving a certain level of HBsAg reduction.

As a result of the misleading statements and omissions, Altimmune, Inc. stock prices dropped significantly when the truth about the HepTcell Phase 1/2 clinical trial was revealed. This drop in stock prices caused financial harm to investors who had purchased Altimmune, Inc. securities during the specified time period.

Investors who suffered financial losses due to their investment in Altimmune, Inc. securities during the relevant time frame may be eligible to participate in the class action lawsuit. It is important for affected investors to take action before the upcoming deadline to ensure that their rights are protected.

Levi & Korsinsky, LLP is a leading securities litigation firm that has a proven track record of successfully representing investors in class action lawsuits. The firm specializes in holding companies accountable for their wrongdoing and securing financial compensation for investors who have suffered losses as a result of securities fraud.

If you are an investor who purchased Altimmune, Inc. securities between May 18, 2021, and August 30, 2021, and would like to learn more about your legal rights and options in the class action lawsuit, contact Levi & Korsinsky, LLP today. It is important to act quickly to protect your rights and seek the financial compensation you may be entitled to.